Literature DB >> 8792944

Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis.

M Amodio-Groton1, A Madu, C N Madu, L L Briceland, M Seligman, P McMaster, M H Miller.   

Abstract

OBJECTIVE: To compare, in patients with gram-negative bacteremia, a course of parenteral antibiotic therapy alone with initial parenteral therapy followed by oral ciprofloxacin in terms of the length of hospitalization, clinical effectiveness, toxicity, and cost.
DESIGN: A prospective, controlled, randomized, open trial in select hospitalized patients.
SETTING: Large metropolitan teaching hospital. PATIENTS: Fifty hospitalized patients with proven gram-negative bacteremia were randomized to receive either oral ciprofloxacin (group 1) following a 72-hour initial intravenous antibiotic regimen or to continue parenteral therapy alone (group 2). To compare the length of hospitalization, an additional group of 50 hospitalized patients with bacteremia (not enrolled in the study, group 3) were analyzed. INTERVENTION: Parenteral antibiotics for 72 hours followed by continuation of a parenteral regimen or oral ciprofloxacin 750 mg bid. MAIN OUTCOME MEASURES: Clinical response, toxicity, and length of hospitalization.
RESULTS: Clinical resolution was comparable in the 24 group 1 patients receiving intravenous antibiotics followed by oral ciprofloxacin (83%), the 26 group 2 patients receiving parenteral therapy alone (77%), and the 50 comparison patients (76%). There was little toxicity noted in any group, and the initial parenteral antibiotic regimens were similar. The mean numbers of hospital days on antibiotics were 9.1, 11.2, and 10.6 days in groups 1,2, and 3, respectively (p < 0.05 for group 1 vs. group 2 or 3), and the lengths of hospitalization were 9.8, 15.7, and 12.1 days, respectively (p < 0.05 for group 1 vs. group 2 or 3). Shortening the length of hospitalization and days of antibiotic therapy was associated with a cost savings of up to $78 000 for group 1 patients.
CONCLUSIONS: Parenteral therapy for 72 hours followed by oral ciprofloxacin significantly shortened both the number of hospital days taking antibiotics and the length of stay compared with parenteral therapy alone. Both regimens were equally effective and safe in the therapy of gram-negative bacteremia, and initial parenteral therapy followed by oral ciprofloxacin was cost-effective.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8792944     DOI: 10.1177/106002809603000605

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  11 in total

1.  Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients.

Authors:  D N Fish; E Abraham
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Target site concentrations of ciprofloxacin after single intravenous and oral doses.

Authors:  Martin Brunner; Heino Stabeta; Jan-Georg Möller; Claudia Schrolnberger; Boban Erovic; Ursula Hollenstein; Markus Zeitlinger; Hans Georg Eichler; Markus Müller
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

3.  An evaluation of quinolone prescribing in a group of acute hospitals: development of an objective measure of usage.

Authors:  C Curtis; R Fitzpatrick; J F Marriott
Journal:  Pharm World Sci       Date:  2002-04

4.  General principles of antimicrobial therapy.

Authors:  Surbhi Leekha; Christine L Terrell; Randall S Edson
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

5.  Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study.

Authors:  Noah Wald-Dickler; Todd C Lee; Soodtida Tangpraphaphorn; Susan M Butler-Wu; Nina Wang; Tyler Degener; Carolyn Kan; Matthew C Phillips; Edward Cho; Catherine Canamar; Paul Holtom; Brad Spellberg
Journal:  Open Forum Infect Dis       Date:  2021-12-23       Impact factor: 3.835

6.  Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review.

Authors:  Noah Wald-Dickler; Paul D Holtom; Matthew C Phillips; Robert M Centor; Rachael A Lee; Rachel Baden; Brad Spellberg
Journal:  Am J Med       Date:  2021-10-27       Impact factor: 4.965

7.  Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections.

Authors:  Joshua T Thaden; Pranita D Tamma; Yohei Doi; Nick Daneman
Journal:  Int J Antimicrob Agents       Date:  2021-10-20       Impact factor: 5.283

8.  Intravenous-only or Intravenous Transitioned to Oral Antimicrobials for Enterobacteriaceae-Associated Bacteremic Urinary Tract Infection.

Authors:  Krista L Rieger; John A Bosso; Shawn H MacVane; Zachary Temple; Amy Wahlquist; Nicole Bohm
Journal:  Pharmacotherapy       Date:  2017-10-23       Impact factor: 4.705

9.  Intravenous to oral conversion of fluoroquinolones: knowledge versus clinical practice patterns.

Authors:  Ornella Conort; Steven Gabardi; Marie-Pauline Didier; Georges Hazebroucq; Alain Cariou
Journal:  Pharm World Sci       Date:  2002-04

10.  Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice.

Authors:  Chia-Chih Liao; Huang-Ping Yu; Shih-Chun Yang; Ahmed Alalaiwe; You-Shan Dai; Fu-Chao Liu; Jia-You Fang
Journal:  J Nanobiotechnology       Date:  2021-02-15       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.